Takhzyro ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

takhzyro

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedeema, perinnöllinen - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Alunbrig ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

alunbrig

takeda pharma a/s - brigatinib - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Slenyto ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

slenyto

rad neurim pharmaceuticals eec sarl - melatoniini - sleep initiation and maintenance disorders; autistic disorder - psyykenlääkkeiden - slenyto on indikoitu unettomuuden hoitoon lapsilla ja nuorilla iältään 2-18 kanssa autismin kirjon (asd) ja / tai smith-magenis-oireyhtymä, jossa nukkua hygienia toimenpiteet ovat olleet riittämättömiä.

Veyvondi ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

veyvondi

baxalta innovations gmbh - vonicog alfa - von willebrandin taudit - hemostaatit - veyvondi on tarkoitettu aikuisten (ikä 18 ja vanhemmat) ja von willebrandin tauti (vwd), kun desmopressiini (ddavp) hoito yksin on tehoton tai sitä ei ole merkitty varten - hoito verenvuoto ja kirurginen verenvuoto - ehkäisy kirurginen verenvuoto. veyvondi ei pitäisi käyttää hoitoon hemofilia a.

Quofenix ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

quofenix

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumiini - yhteisön hankkimat infektiot - systeemiset bakteerilääkkeet, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 ja 5. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Trixeo Aerosphere ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

trixeo aerosphere

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Riltrava Aerosphere ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

riltrava aerosphere

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Livtencity ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

livtencity

takeda pharmaceuticals international ag ireland branch - maribavir - sytomegalovirusinfektiot - antiviraalit systeemiseen käyttöön - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). on otettava huomioon viralliset ohjeet asianmukaista käyttöä antiviraalisten aineiden.

Qdenga ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - - rokotteet - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Pheburane ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

pheburane

eurocept international b. v. - natriumfenyylibutyraattia - karbamoyyli-phosphate synthase - puutostauti - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet - kroonisen hallinnan urean kierron häiriöt.